RxDoctor Payments Data

Lei Charlton, MD

Internal Medicine · Richmond, VANPI 1427146133

Payments from drug & device makers

$3,681in general payments, 2019–2025

Across 116 payments — averaging $31.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Amarin Pharma, Inc.$527
  • Lilly USA, LLC$280
  • Vanda Pharmaceuticals Inc.$205
  • Medtronic$127
  • AbbVie$112
  • plus $566 from 16 others

What the payments were for

  • Food & beverage$3,681100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,681 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$26,327
Medicare patients
71
Services billed
212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin36$51,043
OzempicSemaglutide17$24,069
JanuviaSitagliptin Phosphate12$16,647
EliquisApixaban14$14,186
VascepaIcosapent Ethyl13$9,792
Tresiba Flextouch U-100Insulin Degludec11$8,202
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$5,808
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$2,985
Rosuvastatin Calcium124$2,615
Albuterol Sulfate HfaAlbuterol Sulfate69$1,950
Pravastatin Sodium90$1,652
Amlodipine Besylate255$1,564
Ezetimibe60$1,554
Nano 2nd Gen Pen NeedlePen Needle, Diabetic25$1,553
Labetalol Hcl34$1,526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,864$24,06917 claims
MerckJanuvia$24$16,64712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →